Exogenous GM3 ganglioside inhibits atherosclerosis via multiple steps: A potential atheroprotective drug

Ao, Meiying; Wang, Kun; Zhou, Xing; Chen, Guo; Zhou, Yun; Wei, Bo; Shao, Wenxiang; Huang, Jie; Liao, Huanhuan; Wang, Zhexuan; Sun, Yanan; Zeng, Sufen; Chen, Yong

doi:10.1016/j.phrs.2019.104445

Cited by 13 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exploration of the molecular mechanisms by which CDs exert their pharmacological effects revolves around lipid metabolism, with Zimmer et al 69 demonstrating that CDs act by reversing cholesterol transport, promoting cholesterol metabolism and cell reprogramming, and reducing the expression of proinflammatory genes. Chen et al 4,70–73 revealed possible mechanisms of atherosclerosis retardation by CDs through a series of studies: ① CDs affect the structural components of LDL and inhibit its oxidation; ② CDs alter the composition of HDL and inhibit its oxidation; ③ CDs inhibit the secretion of adhesion molecules ICAM‐1, VCAM, E‐Selectin, cytoskeleton, and their related molecules; downregulate adhesion molecule expression probably via the LPS‐IKK‐NF‐κB or oxLDL‐Akt‐NF‐κB pathway; significantly inhibit the adhesion of monocytes to endothelial cells; and affect the key steps of atherosclerosis formation. Meanwhile, the molecular mechanisms by which CDs act based on the classical AMPK signaling pathway with emerging dimensions such as cell autophagy were also explored.…”

Section: Discussionmentioning

confidence: 99%

Cyclodextrins as therapeutic drugs for treating lipid metabolism disorders

Wu,

Li,

Shao

et al. 2024

Obesity Reviews

Self Cite

View full text Add to dashboard Cite

SummaryObjectiveThis study sought to systematically compare the efficacy and mechanism of cyclodextrins as drug interventions in lipid metabolism diseases, potentially providing ideas for subsequent research directions and clinical applications.MethodsWe used the bibliometric method for feature mining, applied VOSviewer software for clustering analysis, and applied content analysis for objective descriptions and accurate analysis.Results(1) We collected more than 50 studies, which is the basic database of this study. (2) The academic bubble map showed that this research area was popular in the United States. (3) Cluster analysis showed that the intensively studied diseases in this field were Niemann–Pick type C (NPC), atherosclerosis (AS), and obesity. The hot‐spot cyclodextrin types were HP‐β‐CD. (4) Literature measurement revealed the involvement of 15 types of lipid metabolism diseases. Among them, NPC, diabetes, and obesity were studied in clinical trials. Dyslipidemia and AS have been reported relatively more frequently in animal experiments. The studies of cellular experiments provide insight into the molecular mechanisms that intervene in lipid metabolism diseases from multiple perspectives. The exploration of the molecular mechanisms by which cyclodextrins exert their pharmacological effects mainly revolves around lipid metabolism.ConclusionIt is worthwhile to investigate the role and mechanism of cyclodextrins in other lipid metabolism diseases. The potential efficacy evaluation of cyclodextrins as pharmaceutical drugs for oral or injectable formulations is less studied and may become a new focus in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Cyclodextrins as therapeutic drugs for treating lipid metabolism disorders

Wu,

Li,

Shao

et al. 2024

Obesity Reviews

Self Cite

View full text Add to dashboard Cite

show abstract

“…LDL oxidation was confirmed by detecting electrophoretic mobility via agarose gel electrophoresis, malondialdehyde (MDA) production via TBARS assay kit, and dynamic conjugated diene (CD) formation, respectively as reported previously [8,9]. The LDL samples were oxidized for the indicated periods of time.…”

Section: Confirmation Of Ldl Oxidationmentioning

confidence: 98%

Dynamic AFM detection of the oxidation-induced changes in size, stiffness, and stickiness of low-density lipoprotein

Wang

Luo

et al. 2020

J Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

Background Low-density lipoprotein (LDL) is an important plasma lipoprotein transporting lipids to peripheral tissues/cells. The oxidation of LDL plays critical roles in atherogenesis and its oxidized form (oxLDL) is an important risk factor of atherosclerosis. The biomechanical properties of LDL/oxLDL are closely correlated with the disease. To date, however, the oxidation-induced changes in size and biomechanical properties (stiffness and stickiness) of LDL particles are less investigated. Methods In this study, copper-induced LDL oxidation was confirmed by detecting electrophoretic mobility, malondialdehyde production, and conjugated diene formation. Then, the topographical and biomechanical mappings of LDL particles before/after and during oxidation were performed by using atomic force microscopy (AFM) and the size and biomechanical forces of particles were measured and quantitatively analyzed. Results Oxidation induced a significant decrease in size and stiffness (Young’s modulus) but a significant increase in stickiness (adhesion force) of LDL particles. The smaller, softer, and stickier characteristics of oxidized LDL (oxLDL) partially explains its pro-atherosclerotic role. Conclusions The data implies that LDL oxidation probably aggravates atherogenesis by changing the size and biomechanical properties of LDL particles. The data may provide important information for a better understanding of LDL/oxLDL and atherosclerosis.

show abstract

“…The extraction of total RNA via the E.Z.N.Z. Total RNA Kit (OMEGA, USA), the synthesis and amplification of cDNA via the HiFiScript cDNA Synthesis Kit (ComWin Biotech Co., Ltd., Beijing, China), and the used primer sequences for ICAM-1 and GAPDH (an internal reference) have been reported in our previous studies (Ao et al 2019;Zhang et al 2019). The cDNA was detected by electrophoresis on a 0.8% agarose gel at 110 V for 25 min and imaged using a gel imaging system (GelDoc 2000, Bio-Rad, CA).…”

Section: Measurement Of Icam-1 Mrna Expressionmentioning

confidence: 99%

“…The extracted proteins were denatured by heating at 95 C. The total protein concentration was quantified by a BCA protein assay. Protein samples in loading buffer were separated, transferred to nitrocellulose (NC) membranes, immune-stained, and chemiluminescent detected as reported in our previous study (Ao et al 2019). The monoclonal antibodies against the key molecules of LPS and oxLDL pathways including P65, phosphorylated P65 (pP65), IKKa, AKT1, and phosphorylated AKT1 (pAKT1), as well as anti-GAPDH (an internal control) mAb and horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG, were all purchased from Abcam (UK).…”

Section: Western Blotmentioning

confidence: 99%